[Chemotherapy in colon cancer].
The aim of the study is to improve the overall survival rates of patients with colon cancer, analyzing the results of chemotherapy in municipal institution «Precarpathian Clinical Oncology Center» and determining the appropriate scheme of chemotherapy in correlation with the stage of the disease. Materials and methods: The basis of the study was the results of the observation of 973 patients with colon cancer (CC). The direct and long-term results of chemotherapy of colon cancer were studied and evaluated. All patients were divided according to the stage of the disease (TNM system). Patients with Stage II, III and IV colon cancer were included into the study. Within each stage of CC patients were divided into groups, depending on the received chemotherapy (FOLFOX, FOLFIRI, XELOX, Mejo, or phthorafurum). The overall survival rate of patients was determined within each stages of colon cancer, the treatment received and the total number of patients. Results: In patients with Stage IV CC, FOLFIRI and FOLFOX prevailed in chemotherapy - 40.7& and 37.3& respectively. 8.5& of patients received XELOX and 6.8& of patients received Mejo. The same percentage of patients received monotherapy with phthorafurum. In chemotherapy most of the patients with Stage III CC received FOLFOX - 42.9&, FOLFIRI and Mejo- 18.1& and 27.6& of patients respectively. Another 10.5& of patients received mono-chemotherapy with phthorafurum. In chemotherapy of patients with Stage II CC, most patients received Mejo and mono-chemotherapy with phthorafurum.- 28.8& and 32.2& of patients. FOLFOX was received by 18.4& of patients, FOLFIRI - by 13.8&, and XELOX - by 5.9& of patients. Conclusions: In patients with Stage II CC Mejo was the most effective PCT scheme - the highest percentage of patients who survived in a 5- year observation. In patients with StageIII CC, the same index is the best in the group of patients who received FOLFOX. In patients with Stage IV CC FOLFIRI was the most effective (the highest percentage of patients who survived) in a one-, two- and three-year observation.